| Ytd | -22.16% | |
| 1y | 44.44% |
| Open | 1.33 | Prev Close | 1.31 | Low | 1.29 | High | 1.33 | Mkt Cap | 324.09M |
| Vol | 773.85K | Avg Vol | 1.56M | EPS | -0.29 | P/E | N/A | Forward P/E | -3.66 |
| Beta | 1.28 | Short Ratio | 35.21 | Inst. Own | 50.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.33 | 200-d Avg | 1.60 | 1yr Est | 4.83 |
LCTX News
On Tuesday, Lineage Cell Therapeutics (AMEX:LCTX) discussed first-quarter financial results during i
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.03) per share which missed th
US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX)
New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturi
$100,000,000 Common SharesPreferred SharesDebt SecuritiesWarrants From time to time, we may offer up
Other Events.On March 11, 2026, Lineage Cell Therapeutics, Inc. (the "Company") filed with t
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly earnings of $0.00 per share which beat the
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy
HC Wainwright & Co. analyst Joseph Pantginis maintains Lineage Cell Therapeutics (AMEX:LCTX)
On November 12, 2025, Lineage Cell Therapeutics, Inc. (the "Company") sold 12,000,000 common
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed th
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology compa
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy
Three-year term intended to advance preclinical development of ReSonanceUp to $12 million of develop
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.07) per share which missed th
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.13) per share which missed th
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy
The DOSED study is designed to evaluate the safety and utility of a new parenchymal spinal delivery
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX)
Mean vision gains of +9 letters among patients with extensive coverage of OpRegen cell therapy to th
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.02) per share which beat the
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology compa
Fully Virtual Event Scheduled for June 27, 2025Lineage Cell Therapeutics, Inc. (NYSE American and TA
B. Riley Securities analyst Mayank Mamtani maintains Lineage Cell Therapeutics (AMEX:LCTX) with a
D. Boral Capital analyst Jason Kolbert maintains Lineage Cell Therapeutics (AMEX:LCTX) with a Buy
HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX)
Lineage Cell Therapeutics (AMEX:LCTX) reported quarterly losses of $(0.02) per share which beat the